The BEACON trial [18] first demonstrated that both a dual therapy targeting BRAF (encorafenib) and EGFR (cetuximab) and especially a triple combination targeting BRAF (encorafenib), MEK (binimetinib), and EGFR (cetuximab) can increase the survival of colon cancer patients compared to the current standard of care (SoC). Here, MAP2K7 is linked to malignant colon neoplasm.